In fact, demand for GLP-1 therapies has grown so rapidly that the World Health Organization (WHO) issued an advisory to its members last December, warning of the spread of falsified and substandard products that threaten patient safety and public trust
He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools
Reference link: Levothyroxine (thyroid hormone) oral semaglutide label reports increased levothyroxine exposure
The FLOW trial for semaglutide kidney outcomes in T2DM halted due to interim results meeting efficacy criteria FLOW is a RCT comparing injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care on kidney outcomes in people with type 2 diabetes and chronic kidney disease
Not blind optimism, but confidence in our ability to respond, adapt, and choose again